Skip to content

A Study on the Efficacy and Mechanism of Voluntary Slow Breathing Training Combined with Comprehensive Decongestive Therapy for Breast Cancer-Related Upper Limb Lymphedema

A Study on the Efficacy and Mechanism of Voluntary Slow Breathing Training Combined with Comprehensive Decongestive Therapy for Breast Cancer-Related Upper Limb Lymphedema

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600115987
Enrollment
Unknown
Registered
2026-01-04
Start date
2026-01-04
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer-related lymphedema

Interventions

Test group:Slow Breathing Training Combined with Comprehensive Edema Reduction Therapy

Sponsors

Jing'an District Central Hospital Of Shanghai
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Female, aged 30 to 75; 2. Upper limb lymphedema diagnosed after unilateral breast cancer surgery (ISL stage I-II); 3. At least 3 months after the completion of surgery, radiotherapy and chemotherapy, the condition is stable and there is no evidence of disease recurrence. 4. Be capable of understanding and implementing breathing training instructions; 5. The patient or their family members sign the informed consent form and voluntarily participate in this study.

Exclusion criteria

Exclusion criteria: 1.ISL Stage III severe lymphedema or acute infections such as erysipelas; 2.Bilateral lymphedema or limb swelling due to other causes (cardiac, renal, etc.); 3.The affected limb has an active tumor or metastasis. 4.Individuals with known neurological disorders affecting autonomic nervous system function (such as Parkinson's disease); 5.Severe cognitive impairment or mental illness; 6.Severe cardiopulmonary disease (NYHA Class III-IV, resting dyspnea), respiratory dysfunction, or active pulmonary infection; 7.Deep vein thrombosis of the upper extremities or uncontrolled hypertension (>=160/100 mmHg), implantation of a cardiac pacemaker or defibrillator; 8.Currently taking medications that affect autonomic nervous system function (such as beta-blockers); 9.Received treatment for systemic lymphedema within the past 3 months or participated in other clinical trials;

Design outcomes

Primary

MeasureTime frame
PHQ-9;Upper Arm Circumference/Volume;

Secondary

MeasureTime frame
FACT-B(V4.0);Handgrip strength test;6-minute walk test;heart rate variability;International Physical Activity Questionnaire;Ultrasound imaging;GAD-7;LYMPH-Q;

Countries

China

Contacts

Public ContactJia Jie;Yang Feixue

Shanghai Jing'an District Central Hospital

shannonjj@126.com+86 21 5288 7820

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026